Business
Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting
Experienced Urologists to Present Latest Findings and Host Multiple Educational SessionsWAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innova
About this update from Teleflex Incorporated
[{"type":"image","alt":"Teleflex Incorporated","displaySize":"","headline":null,"caption":"Teleflex Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/b2d67c9a50caa1f1cddeda86b58ff1b8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hWX2O.eEUBx79Dv.M4CvaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b2d67c9a50caa1f1cddeda86b58ff1b8","width":300,"height":125}},"lazy":false},{"type":"text","content":"Experienced Urologists to Present Latest Findings and Host Multiple Educational Sessions","length":88,"tagName":"p"},{"type":"text","content":"WAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing to protect tissue during radiation treatment for prostate cancer.","length":550,"tagName":"p"},{"type":"text","content":"“Understanding how leading treatment options perform—both in rigorous clinical trials and in everyday practice—is essential to empowering the future of healthcare for patients,” said Travis Gay, president and general manager of Teleflex Interventional Urology. “At Teleflex, we are deeply committed to advancing evidence-based innovation. Through ongoing real-world clinical trial research, we continue to support the safe and effective use of the UroLift™ System and Barrigel™ rectal spacer, helping physicians enhance outcomes and quality of life for patients.”Clinical Study Presentations:","length":594,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Results from the CLEAR Randomized Controlled Trial (RCT) Suggest Factors Corresponding to Early Patient Satisfaction Are Better Following UroLift PUL Versus Rezum WVTT†– Moderated Poster Presentation; Saturday, April 26, 3:30–5:30 pm in Casanova, Room 505The CLEAR randomized controlled trial compares patient outcomes between UroLift™ PUL and Rezum WVTT.1 The presentation is being moderated by Dr. Bilal C...